BRIEF-Prana Biotechnology says met primary endpoint in phase 2 of Huntington Disease trial

Feb 18 (Reuters) - Prana Biotechnology Ltd PBT.AX :

* Prana announces successful phase 2 results in hd trial PBT.AX

* Sees plans to advance pbt2 to a confirmatory phase 3 clinical trial

* Says primary endpoints of safety and tolerability met

* Says no significant improvements were seen on other secondary efficacy measures in the study

* Source text for Eikon News Search ID:nASX2bfvlQ

* ((For more news, please click here PBT.AX ))

((Bangalore Newsroom; +91 80 6749 1130))